GEN
Allergan is paying Polyphor $7 million upfront to use the latter’s protein epitope mimetics technology (PEM) to find drugs for eye diseases. This license and discovery partnership is worth about $68 million in milestones.
Allergan and Polyphor will conduct a research program to identify PEM cytokine inhibitors suited for local delivery to the eye using Allergan’s drug delivery systems.